All In Biotech

Drug Trial Radar · NCT07213609

A Study to Investigate the Safety and Preliminary Efficacy of GSK5460025 Alone or in Combination With Other Anti-cancer Agents in Participants With Solid Tumors

A Phase 1/2 Open-label, Multicenter Study of Oral GSK5460025 Alone or in Combination With Other Anti-cancer Agents in Adult Participants With Mismatch Repair-deficient (dMMR) or Microsatellite Instability-High (MSI-H) Solid Tumors

Last checked: Nov 20, 2026Latest source record: Nov 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

47

Planned (sponsor's estimate)

Start

Oct 20, 2025

Primary completion

Sep 28, 2028

Study completion Oct 27, 2028

Sponsor

Lead sponsor
GlaxoSmithKlineGSK (GSK)
Sponsor type
Industry
First posted
Oct 9, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Solid tumours are abnormal lumps of tissue that can occur in different parts of the body. The tumours involved in this study have specific genetic characteristics that can make them more aggressive and challenging to treat. The study will test whether GSK5460025 alone or in combination (potential combinations may be included in future amendments to the protocol) with other anti-cancer agents can decrease tumor size, is safe, well-tolerated, and how the drug is processed in the body over time.

Conditions

  • Neoplasms, Colorectal
  • Neoplasms

Interventions

  • GSK5460025Drug

    GSK5460025 will be administered

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Part 1: Number of participants with dose limiting toxicities (DLTs) per dose levelTime frame: Up to 28 days
  2. Part 1: Number of participants with treatment emergent serious adverse events (TESAEs) and treatment emergent adverse events (TEAEs) by severity per dose levelTime frame: Up to approximately 33 months
  3. Part 1: Number of participants with TESAEs and TEAEs by severity per dose level during DLT observation periodTime frame: Up to 28 days
  4. Part 1: Number of participants with dosage modifications due to TEAEs per dose levelTime frame: Up to approximately 33 months
  5. Part 2: Objective Response Rate (ORR)Time frame: Up to approximately 33 months

Locations

27 sites in 9 countries. Site status is shown where the registry gives one.

  • GSK Investigational Site

    Aurora, Colorado · Recruiting

  • GSK Investigational Site

    Detroit, Michigan · Recruiting

  • GSK Investigational Site

    Canton, Ohio · Recruiting

  • GSK Investigational Site

    Nashville, Tennessee · Recruiting

  • GSK Investigational Site

    Hamilton, Ontario, Canada · Recruiting

  • GSK Investigational Site

    Toronto, Ontario, Canada · Recruiting

  • GSK Investigational Site

    Montreal, Quebec, Canada · Recruiting

  • GSK Investigational Site

    København Ø, Capital Region, Denmark · Recruiting

  • GSK Investigational Site

    Lyon, France · Recruiting

  • GSK Investigational Site

    Saint-Herblain, France · Recruiting

  • GSK Investigational Site

    Villejuif, France · Recruiting

  • GSK Investigational Site

    Milan, Italy · Recruiting

  • GSK Investigational Site

    Milan, Italy · Recruiting

  • GSK Investigational Site

    Chiba, Japan · Recruiting

  • GSK Investigational Site

    Osaka, Japan · Recruiting

  • GSK Investigational Site

    Tokyo, Japan · Recruiting

  • GSK Investigational Site

    Tokyo, Japan · Recruiting

  • GSK Investigational Site

    Amsterdam, Netherlands · Recruiting

  • GSK Investigational Site

    Utrecht, Netherlands · Recruiting

  • GSK Investigational Site

    Barcelona, Spain · Recruiting

  • GSK Investigational Site

    Madrid, Spain · Recruiting

  • GSK Investigational Site

    Madrid, Spain · Recruiting

  • GSK Investigational Site

    Madrid, Spain · Recruiting

  • GSK Investigational Site

    Madrid, Spain · Recruiting

  • GSK Investigational Site

    Lund, Sweden · Recruiting

  • GSK Investigational Site

    Stockholm, Sweden · Recruiting

  • GSK Investigational Site

    Uppsala, Sweden · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.